← Human Trials & Peer-Reviewed Studies
Effect of growth hormone administration on human ovarian function and steroidogenic gene expression in granulosa-luteal cells.
Plain-language guide to PMID 1426317 (1992): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 1426317
- Journal
- Fertility and sterility
- Year
- 1992
- Study type
- Randomized Controlled Trial
- Authors
- Tapanainen J et al. (6 authors)
- DOI
- 10.1016/s0015-0282(16)55319-9
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
To study the effect of growth hormone (GH) in combination with an ultrashort-term gonadotropin-releasing hormone analogue/human menopausal gonadotropin (hMG)/human chorionic gonadotropin (hCG) regimen in ovarian hyperstimulation for in vitro fertilization (IVF).
Who Took Part
PubMed indexes the participants as adults, women only.
Fifty-four normally cycling women (27 control and 27 GH-treated) participated in this study.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
What Was Measured
Topics PubMed links to this paper include Estradiol, Follicle Stimulating Hormone, Follicular Fluid, Gene Expression, Granulosa Cells, Growth Hormone and Insulin-Like Growth Factor I.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1992 (Fertility and sterility), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.